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was used to assess the population level public health and economic impact of
infant anti-pneumococcal vaccination. The alternatives compared were: no vacci-
nation (comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were:
child illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs)
gained. Effectiveness and utilities were obtained from literature. Local costs (ex-
pressed in 2011 $US) and epidemiology (data from 2009-2011) were obtained from
Panamá=s official databases. Univariate sensitivity analysis was performed. The
time horizon for total costs was one year and for outcomes was lifetime with a
discount rate of 3%. RESULTS: Results show that immunization is cost-saving
against no-vaccination. PCV-13 gained the highest number of QALYs (305) against
PCV-10 (191) and PCV-7 (168). PCV-13 prevented 629 illnesses and gained 334 LYs.
PCV-10 and PCV-7 prevented 392 and 359 illnesses and gained 208 and 182 LY=s,
respectively. Total costs of illness with PCV-13, PCV-10, PCV-7 and no vaccination
were $622,445, $777,878, $804,978 and $1,005,512, respectively. These results were
robust to variations in herd immunity and impact adjustments of PCV-10
immunogenicity. CONCLUSIONS: This is the first cost-effectiveness study for anti-
pneumococcal immunization in Panamá. Immunization strategies based on 7, 10
and 13-valent PCV=s may be cost-saving interventions compared to no vaccination.
PCV-13 dominates PCV-10 and PCV-7.
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OBJECTIVES: . Pneumococcal bacteremia and pneumonia are priority diseases for
public health in Guatemala since these are among the 10 most frequent causes of
hospitalizations and mortality in children under 4 years old. The aim of this study
was to estimate the cost-effectiveness of immunization strategies based on pneu-
mococcal conjugate vaccines (PCVs) in Guatemala, from an institutional
perspective.METHODS: . A decision tree steady state model was used to assess the
population level public health and economic impact of infant anti-pneumococcal
vaccination. The alternatives compared were: no vaccination (comparator), PCV-10
and PCV-13. The effectiveness measures were: illness avoided life years gained
(LYs) and quality-adjusted life years (QALYs) gained. Effectiveness and utilities
were obtained from literature. Local costs (expressed in 2011 $US) and epidemiol-
ogy (data from 2009-2011) were obtained from Guatemala=s official databases. Uni-
variate sensitivity analysis was performed. The time horizon for total costs was one
year and for outcomes was lifetime with a discount rate of 3%. RESULTS: . Results
show that immunization is cost-saving against no-vaccination. PCV-13 gained
more QALYs (7,569) against PCV-10 (5,824). PCV-13 prevented 5658 illnesses and
gained 8404 LYs, while PCV-10 prevented 4140 illnesses and gained 6465 LYs. Total
costs of illness with PCV-13, PCV-10 and no vaccination were $2,599,952, $3,071,811
and $5,534,657, respectively. These results were robust to variations in herd immu-
nity and impact adjustments of PCV-10 immunogenicity. CONCLUSIONS: . This is
the first cost-effectiveness study for anti-pneumococcal immunization developed
in Guatemala. Immunization strategies based on 10 and 13-valent PCV=s may be
cost-saving interventions. PCV-13 dominates PCV-10.
PIN65
HEALTH ECONOMIC MODEL ON THE COSTS AND EFFECTS OF ROTA VIRUS
VACCINATION IN GERMANY
Knoll S1, Benter U2, Standaert B3
1GlaxoSmithKline GmbH & Co. KG, Munich, Bavaria, Germany, 2Kendle GmbH, Munich, Bavaria,
Germany, 3GlaxoSmithKline Biologicals, Wavre, Belgium
OBJECTIVES: Rotavirus gastroenteritis (RVGE) is one of the most frequent diseases
among children aged 5 or younger. A general recommendation for rotavirus vacci-
nation in Germany does not exist so far, leading to a vaccination rate of 30%. This
analysis simulates the cost-effectiveness of a general rotavirus vaccination in Ger-
many using Rotarix™ from the perspective of the statutory health insurance (SHI).
METHODS:An existing Markov model on rotavirus infection in children (published
before) was adapted to the German situation. The model simulates costs and ef-
fects of rotavirus vaccination in a birth cohort of 699,301 children. In the model,
vaccine efficacy rates from international clinical trials were combined with Ger-
man epidemiology and cost data from the SHI perspective for 2011 (including SHI
reimbursed productivity losses of parents). The model assumes a vaccination rate
of 100% and discount rates of 3% for costs and effects. Results were tested for
robustness using sensitivity analyses. RESULTS: A 100% vaccination with Rotar-
ixTM could avoid approximately 156,000 RVGE cases and associated physician vis-
its as well as in-patient hospital stays. From the SHI perspective, this leads to cost
savings of 13.6 Mio € in total. The main factors responsible for these savings are
in-patient hospital stays avoided (64.1 Mio €), SHI reimbursed productivity losses of
parents (19.0 Mio €) and physician visits avoided (5.4 Mio €). On the other hand,
vaccination costs amount to additional 79.4 Mio €. Stability of results was most
sensitive with respect to epidemiological parameters (number of RVGE cases, in-
patient hospital cases) as well as productivity loss. CONCLUSIONS: A general™
vaccination against rotavirus in Germany can avoid severe diarrhea events in chil-
dren aged 5 and younger. Additional vaccination costs for the SHI are more than
outbalanced by cost savings through in-patient hospital stays, SHI reimbursed
productivity loss and physician visits avoided.
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OBJECTIVES: To estimate the cost of virologic failure with the treatment of etra-
virine and raltegravir in multi-experienced patients in the Brazilian National AIDS
Program. METHODS: Treatment regimens of etravirine and raltegravir were de-
fined by the guidelines of the Brazilian National AIDS Program. Upon virologic
failure, subsequent treatments were defined according to the same guidelines con-
sidering new drug combinations not yet used by the patients. Treatment costs
considered the cost of medication as purchased by the Brazilian government and
published on their website. As maraviroc, a rescue treatment, is not yet reimbursed
by the AIDS program, its price was defined by law. To estimate the total cost,
patient numbers were calculated by the number of capsules of raltegravir dis-
pensed in the past 96 weeks, and assumed the same for patients treated with
etravirine. Virologic failure was gathered from the phase III clinical trials of ralte-
gravir and etravirine at week 48 and week 96. RESULTS: The average cost of treat-
ment for multi-failure patients with etravirine was on average R$ 26.692,26 at week
48 of treatment compared to R$ 26.634,15 per patient treated with raltegravir. At
week 96, the average treatment cost per patient was R$ 56.810,59 for raltegravir and
R$ 53.904,30 for etravirine. Given that 3.942 patients received treatment in the
previous 98 weeks, around 1.301 patients will fail treatment with raltegravir and
630 with etravirine. The total cost of treating these patients is R$ 73 million for
raltegravir and R$ 34 million for etravirine. CONCLUSIONS: Despite a similar aver-
age cost at week 48, etravirine treatment is a more economic option for the treat-
ment of multi-failure patients compared to raltegravir, saving up to 50% of treat-
ment costs with virologic failure patients in the Brazilian National AIDS program
over 96 weeks. Virologic failure is therefore an important indicator to avoid subse-
quent treatment costs especially in the long-term.
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OBJECTIVES: The analysis aimed to evaluate the cost-effectiveness of 48-week
therapy with peginterferon alpha-2a (PegIFN-2a) in HBeAg-negative chronic hep-
atitis B (CHB) patients versus 48-week (short-term analysis) or 4-year (long-term
analysis) therapy with adefovir, entecavir or lamivudine from the public payer
perspective in Poland. METHODS: A life-time Markov model based on previously
published analysis was used. States encompassed treatment response (ALT nor-
malization), relapse, complications (compensated/decompensated cirrhosis, hep-
atocellular carcinoma, liver transplantation) and death. Quality-adjusted life years
(QALYs) were the measure of effectiveness. Short-term efficacy assessment was
based on the results of randomized clinical trials (RCTs) corrected for response
duration. Long-term efficacy data for nucleos(t)ide analogues (NAs) were derived
from other published models and RCTs extensions. Utilities and transition proba-
bilities (spontaneous response, relapse, complications, death) were derived from
published literature. Direct medical costs, i.e. costs of drugs and procedures used in
the treatment of CHB and its complications were obtained using a survey con-
ducted among Polish clinicians. In the base case analysis costs and benefits were
discounted at a 5% and 3.5% annual rate, respectively. The robustness of the results
was assessed using one-way, scenario and probabilistic sensitivity analyses.
RESULTS: The short and long-term analysis demonstrated that the use of
PegIFN-2a increased QALYs and life years gained (LYGs) compared to all investi-
gated NAs. In the short-term model PegIFN-2a decreased the costs of complica-
tions treatment and increased the overall costs due to drug acquisition cost. ICERs
for PegIFN-2a vs. lamivudine, adefovir or entecavir amounted to 43,621, 6,600 and
25,166 PLN/QALY, respectively (1€4 PLN). In the long-term model PegIFN-2a was
cost-saving and dominated adefovir, while ICERs vs entecavir and lamivudine
amounted to 5,385 and 73,857 PLN/QALY, respectively. Sensitivity analysis proved
these results to be robust. CONCLUSIONS: Peginterferon alfa-2a is cost-effective
when compared to adefovir, entecavir and lamivudine in Poland.
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OBJECTIVES:To estimate cost-effectiveness of the vaccination program with quad-
rivalent Human Papillomavirus (HPV 6, 11, 16, 18) recombinant vaccine for the
prevention of cervical intraepithelial neoplasia (CIN) and cervical cancer (CC) in
Russian health care. METHODS: Cost-effectiveness analysis of vaccination pro-
gram vs no vaccination was performed. The previously published model (R. Insinga
et al.) was adjusted for Russia. Rates of CIN and CC were simulated with and
without vaccination in a cohort of girls 12-13 years old. Time-horizon was 24 years.
100% vaccination coverage was assumed. Direct medical costs were estimated.
Outcomes measured were: the cost of averted CIN case and the cost per additional
life-year saved. RESULTS: The cost of introducing HPV vaccination program with
100% coverage of the target audience of 12-13 years old girls is 408,16 mln €
(16,282,34 bln rubles). In the absence of vaccination the costs of providing medical
care to patients with CIN and CC are 160,027 mln € (6, 36 bln rubles). Therefore the
overall costs in a vaccinated cohort were 481,14 mln € (16,285,25 bln rubles). HPV
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vaccine prevents 408 469 cases of precancerous cervical lesions. Due to HPV vacci-
nation the incidence of CC is reduced by1858 cases, which corresponds to 31 588
years of life saved in the vaccinated cohort. The cost of an additional life-year saved
is 10,166 € (405,535 rubles), and the cost of averted CIN case is 786 € (31,360 rubles).
CONCLUSIONS: Vaccination with Human Papillomavirus recombinant vaccine
seems a cost-effective option in Russia.
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OBJECTIVES: Pertussis incidence has been increasing in adolescents and adults in
the last two decades with transmission to vulnerable young infants. This epidemi-
ological changing has raised interest in the cost-effectiveness of booster vaccina-
tion (extra administration of a vaccine after an earlier dose). A critical review of
economic evaluations of pertussis booster vaccination was performed in order to
develop recommendations for future studies. This review illustrates specific chal-
lenges encountered in economic evaluations of vaccination programmes.
METHODS: The literature search covered cost-effectiveness studies of pertussis
booster vaccination, published until November 2010, worldwide. We extracted in-
formation on model structures, input data and results. RESULTS: We identified 13
publications (9 distinct models) referring to cost-effectiveness of pertussis booster
vaccination. The most frequently studied strategies were adolescent booster vac-
cination (9/13), cocooning strategy, i.e. vaccination of mothers and family mem-
ber(s) of newborn infants (6/13), one-time adult pertussis booster vaccination (6/
13), and decennial vaccination of adults with pertussis containing boosters (4/13).
All studies found that booster vaccination was a cost-effective or cost-saving strat-
egy compared to no booster vaccination. However, conclusions differed concerning
the exact age groups to vaccinate and frequency of vaccination. Results were
strongly affected by assumptions regarding unreported cases and uncertainty
around incidence. Four models ignored herd immunity (HI) effects, 3 assumed
incidence reduction attributable to HI, and 2 were transmission dynamic models
predicting HI effects. Several studies considered incidence at steady state, al-
though it was not reached before 80 years for some strategies. Methods used to
compare multiple strategies were often inappropriate. CONCLUSIONS: Reviewed
studies showed that pertussis booster vaccination is cost-effective or dominant vs.
no booster vaccination, but did not identify any optimal vaccination schedule.
Results are variable due to uncertainty surrounding disease incidence and extent
of HI. Future economic evaluations should explore a wider range of strategies,
according to local context.
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OBJECTIVES: Rotavirus infection causes severe gastroenteritis in children world-
wide. Its disease burden has been reduced in countries where mass rotavirus vac-
cination programmes have been introduced. England and Wales (E&W) have not
yet implemented such a mass vaccination programme, but are currently re-evalu-
ating its potential cost-effectiveness. Our study uses a dynamic model to predict
the epidemiological and economical effect of such a mass vaccination programme
in E&W beginning in the autumn of 2011. METHODS: A previously published age-
structured dynamic model was upgraded and parameterised with country-specific
data for the introduction of the oral rotavirus pentavalent vaccine. We report the
impact of vaccination on disease incidence reduction, timing of seasonal epidem-
ics and herd immunity levels. The model was then used to assess whether a mass
vaccination of RotaTeq is cost-effective and affordable for E&W. RESULTS: Our
results predict that vaccination can reduce the burden of severe disease by 70% and
delay the epidemic peak by two and a half months with coverage of 95%. Our
calculations further show that herd immunity accounts for about a quarter of the
reduction in incidence. If the pentavalent vaccine-induced immunity does not
wane over five years, severe disease in children under five years of age is elimi-
nated within two years after the introduction of vaccination. The probability of a
mass vaccination strategy being cost-effective is presented under likely vaccine
waning scenarios, administration cost assumptions and possible dose prices.
CONCLUSIONS: This work allows policymakers to determine both the epidemio-
logical impact and cost implications of a mass vaccination programme against
rotavirus with the pentavalent vaccine in England and Wales. Although long con-
sidered unlikely to be cost-effective in E&W using static models, the pentavalent
vaccine demonstrates a significant impact in reducing rotavirus cases at accept-
able levels of cost-effectiveness when using appropriate modelling techniques.
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OBJECTIVES: Evaluation of comparative cost-effectiveness of CAP treatment with
moxifloxacin versus combined therapy with cefotaxime and macrolides in adult
patients.METHODS: Patients were randomized in two groups. MOX group received
moxifloxacin 400 mg i.v. once-daily with further switch to oral formulation 400 mg
daily. COMB group received either cefotaxime 1000 mg i.m. 3 times per day as
monotherapy or in combination with oral azithromycin or clarithromycin. Efficacy
and safety criteria were evaluated according to clinical data, laboratory tests and
X-ray examination. Cost-effectiveness analysis was performed. RESULTS: MOX
group included 30 patients, mean age 33.616.5 years; COMB group included 50
patients, mean age 26.515.6 years. The efficacy of moxifloxacin treatment was
96.7%, in-hospital stay duration was 15.93.3 days. The efficacy of treatment in
COMB group was 88.0%, patients were discharged after 18.23.7 days. Direct med-
ical costs including antibacterial treatment and in-hospital days were 46712 RUB
(€1173) in MOX group and 46970 RUB (€1180) in COMB group. CERMOX 48307 RUB
(€1213), CERCOMB 53375 RUB (€1340). CONCLUSIONS: CAP treatment with moxi-
floxacin compared to combined therapy with cefotaxime and macrolides in adult
patients is more effective and cost saving technology.
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OBJECTIVES:To assess the cost-effectiveness of universal rotavirus immunization,
explicitly the use of Rotateq® and affordability of implementing rotavirus immu-
nization based on the Global Alliance for Vaccines and Immunization (GAVI)-sub-
sidized vaccine price in the context of Vietnamese health care system for the next
5 years. METHODS: An age-structured cohort model was developed for the 2009
Vietnamese birth cohort and applied a 5-year time horizon with time cycle of 1
month for 1-year-old children and annually thereafter. Results from no vaccina-
tion and vaccination were compared. Outcomes included rotavirus episodes re-
quiring home-treatment, outpatient visits, hospitalizations and deaths. Multiple
outcomes per rotavirus infection are possible in the model. Acceptability and af-
fordability analyses were done using Monte Carlo simulations. Costs were ex-
pressed in 2009 US$. RESULTS: Rotavirus immunization would not completely
protect under-five-year-old children against rotavirus infection due to partial na-
ture of vaccine immunity, however, would effectively reduce rotavirus severe cases
by 55%. Under the GAVI-subsidized price, the minimum vaccination budget
would be US$1.6 million annually. In the base-case, the incremental cost per qual-
ity-adjusted-life-year (QALY) was US$665 from health care perspective,Vietnam-
ese per-capita-GDP in 2009. Affordability results showed that at the GAVI-subsi-
dized vaccine price, rotavirus vaccination could be affordable in Vietnam.
CONCLUSIONS: Rotavirus immunization in Vietnam would be a cost-effective
health intervention. However, it only becomes affordable under the GAVI’s finan-
cial support. Vaccine price is the most crucial factor to decision-makers regarding
introducing this vaccine into the country’s immunization. Given the high under-
five mortality rate, results showed that rotavirus immunization is the “best hope”
for prevention of rotavirus-related diarrhoeal disease in Vietnam. In the next five
years, Vietnam is definitely in debt to external financial support in implementing
rotavirus vaccination. It is recommended that new and cheaper rotavirus vaccine
candidates be developed to speed up rotavirus vaccines introduction in the devel-
oping world.
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OBJECTIVES: To estimate the cost and effects of initiating treatment with atazana-
vir/r (ATV/r) compared to darunavir/r (DRV/r), lopinavir/r (LPV/r) and efavirenz
(EFV) in treatment-naïve HIV-1 patients in Italy(I), Spain(S), Portugal(P) and UK.
METHODS: HIV-disease progression is modeled using a micro-simulation model.
Health states are a function of HIV-RNA, CD4cells, AIDS defining events (ADEs),
and comorbidities. At model entry patients receive either ATV/r, LPV/r, DRV/r, or
EFV with a treatment backbone. Treatment-sequences are modelled following
treatment discontinuation due to virological failure, adverse events, resistance, or
treatment related co-morbidities. Country-specific patterns for HIV related drug
use were applied to estimate specific treatment sequences; maximized at 8 treat-
ment lines after which patient were assumed to be untreated. Efficacy and tolera-
bility inputs of first line treatments were derived from a Mixed-Treatment-Com-
parison, supplemented by published literature and product-SPCs for remaining
drug specific data for efficacy, tolerability and safety. Occurrence of (non)-AIDS
defining malignancies was linked to current CD4cell count and independent of
therapy. Cost estimates were based on country specific sources. A 25-year time-
horizon was chosen for the base-case analyses. A payer’s perspective was chosen
and country-specific discount rates were applied. RESULTS:Across countries, total
costs per patient who started with ATV/r ranged between €126,947(I) and
€154,285(P). Predicted incremental costs of ATV/r versus comparators ranged be-
tween -€27,004 (S) versus LPV/r and -€13,165 (P) versus EFV. Estimated incremental
QALYs of ATV/r versus comparators varied from -0.68(UK) versus EFV to 0.78(UK)
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